IS4

IS4 is a selective CXCR4 competitive antagonist, with an IC50 of 0.65 nM in THP-1 cells and 38.75 nM in Jurkat cells. IS4 is stable in serum and non-cytotoxic. IS4 competitively binds to CXCR4 with CXCL12, thereby inhibiting CXCL12-induced intracellular Ca2+ release and cancer cell migration. IS4 can be used in the research on the prevention of metastasis of breast cancer, prostate cancer, leukemia, and other diseases[1].

3067986-23-3

12352209

Calcium Channel; CXCR

GPCR/G Protein; Immunology/Inflammation; Membrane Transporter/Ion Channel; Neuronal Signaling

Cancer-programmed cell death

Cancer

O=C(N[C@@H](CCCNC(N)=N)C(N[C@@H](C)C(N[C@H](CSC1=C2C(N(CC#C)C1=O)=O)C(N[C@@H](CCCNC(N)=N)C(N[C@@H](CC3=CC=CC=C3)C(N[C@@H](CC4=CC=CC=C4)C(N[C@@H](CS2)C(O)=O)=O)=O)=O)=O)=O)=O)C

C48H62N14O11S2

1075.22

[1]Hamshaw I, et al. The development of potent, competitive CXCR4 antagonists for the prevention of cancer metastasis. Biochem Pharmacol. 2023 Dec;218:115921.

Room temperature

http://file.medchemexpress.com/batch_PDF/HY-P11019/

Peptides

No Development Reported

CXCR4